Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer.
Cohen R, Jonchère V, De La Fouchardière C, Ratovomanana T, Letourneur Q, Ayadi M, Armenoult L, Buisson A, Sarabi M, Pellat A, Colle R, Paye F, Meeus P, Svrcek M, Duval A, Andre T. Cohen R, et al. Among authors: buisson a. J Immunother Cancer. 2021 Feb;9(2):e001903. doi: 10.1136/jitc-2020-001903. J Immunother Cancer. 2021. PMID: 33579738 Free PMC article.
Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer.
Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger S, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, Ray-Coquard I. Labidi-Galy SI, et al. Among authors: buisson a. Clin Cancer Res. 2018 Jan 15;24(2):326-333. doi: 10.1158/1078-0432.CCR-17-2136. Epub 2017 Oct 30. Clin Cancer Res. 2018. PMID: 29084914
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.
Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Varnier R, et al. Among authors: buisson a. Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021. Front Oncol. 2021. PMID: 34631593 Free PMC article.
Gynecological carcinosarcomas: Overview and future perspectives.
Collet L, González López AM, Romeo C, Méeus P, Chopin N, Rossi L, Rowinski E, Serre AA, Rannou C, Buisson A, Treilleux I, Ray-Coquard I. Collet L, et al. Among authors: buisson a. Bull Cancer. 2023 Nov;110(11):1215-1226. doi: 10.1016/j.bulcan.2023.07.005. Epub 2023 Sep 9. Bull Cancer. 2023. PMID: 37679206
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
Bonnet E, Haddad V, Quesada S, Baffert KA, Lardy-Cléaud A, Treilleux I, Pissaloux D, Attignon V, Wang Q, Buisson A, Heudel PE, Bachelot T, Dufresne A, Eberst L, Toussaint P, Bonadona V, Lasset C, Viari A, Sohier E, Paindavoine S, Combaret V, Pérol D, Ray-Coquard I, Blay JY, Trédan O. Bonnet E, et al. Among authors: buisson a. J Pers Med. 2022 Sep 27;12(10):1595. doi: 10.3390/jpm12101595. J Pers Med. 2022. PMID: 36294734 Free PMC article.
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD, Peron J, Bodmer A, Giraud S, Buisson A, Bonadona V, Gauchat-Bouchardy I, Tredan O, Chappuis PO, Labidi-Galy SI. Friedlaender A, et al. Among authors: buisson a. Breast Cancer Res Treat. 2019 Apr;174(3):775-783. doi: 10.1007/s10549-018-05127-2. Epub 2019 Jan 11. Breast Cancer Res Treat. 2019. PMID: 30635808
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I. Labidi-Galy SI, et al. Among authors: buisson a. Gynecol Oncol. 2019 Nov;155(2):262-269. doi: 10.1016/j.ygyno.2019.09.008. Epub 2019 Oct 8. Gynecol Oncol. 2019. PMID: 31604666
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI. De Talhouet S, et al. Among authors: buisson a. Sci Rep. 2020 Apr 27;10(1):7073. doi: 10.1038/s41598-020-63759-1. Sci Rep. 2020. PMID: 32341426 Free PMC article. Clinical Trial.
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI. De Talhouet S, et al. Among authors: buisson a. Sci Rep. 2020 Nov 2;10(1):19248. doi: 10.1038/s41598-020-76385-8. Sci Rep. 2020. PMID: 33139817 Free PMC article.
302 results